On November 30, 2022 RAPT Therapeutics, Inc. (Nasdaq: RAPT) ("RAPT" or the "Company"), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, reported that its abstract from its ongoing Phase 1/2 study of FLX475 as monotherapy and in combination with pembrolizumab in cancer patients has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Immuno-Oncology Annual Congress taking place December 7-9, 2022 in Geneva, Switzerland (Press release, RAPT Therapeutics, DEC 1, 2022, https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-present-flx475-phase-12-data-european-society [SID1234624694]). The presentation will include data from checkpoint inhibitor-naïve NSCLC patients treated with the combination of FLX475 plus pembrolizumab including their PD-L1 status, and patients with EBV-positive NK/T cell lymphoma treated with FLX475 monotherapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster presentation details as follows:
Title: Phase 1/2 study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer
Abstract #: 187P
Session: Poster Display
Date: Thursday, December 8, 2022
Time: 12:30 – 1:15 p.m. CET
Location: Foyer ABC, Palexpo Exhibition Centre, Geneva, Switzerland
The full abstract is available for viewing on the ESMO (Free ESMO Whitepaper)-IO website at, View Source;r=st~10.